A Double-Blind Study in Healthy Volunteers to Assess the Effect of E7080 on the QTc Interval
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This is a double-blind (vis-a-vis lenvatinib), randomized, placebo-controlled,
three-treatment, three-way crossover study in healthy subjects. There are two phases in this
study: Pre-Randomization and Randomization. The Pre-Randomization Phase consists of Screening
and Baseline Period 1. The Randomization Phase consists of five periods: Treatment Period 1,
Baseline Period 2, Treatment Period 2, Baseline Period 3, and Treatment Period 3. Completion
of study termination procedures will be performed at Visit 11.
Phase:
Phase 1
Details
Lead Sponsor:
Eisai Inc.
Treatments:
Fluoroquinolones Lenvatinib Moxifloxacin Norgestimate, ethinyl estradiol drug combination